Advertisement

News Stories

Nov, 2018

Nov. 10, 2018

CHICAGO The REDUCE-IT cardiovascular outcomes trial results, announced today at the American Heart Association Scientific Sessions in Chicago, met its primary composite endpoint and revealed a reduction in major adverse cardiovascular events (MACE) of 25%.

Download the manuscript online now.

0
No votes yet
Name: Members in the News
Nov, 2018

Nov. 10, 2018

NLA among 12 organizations to co-author, endorse key document for reducing risk of atherosclerotic cardiovascular disease

0
No votes yet
Name: NLA News
Oct, 2018

Oct. 25, 2018

Amgen announced on Wednesday, Oct. 24 it is making evolocumab available at a reduced list price in an effort to improve affordability and access for patients.

The announcement represents positive news for patients at risk for cardiovascular events.

Key outcomes from Amgen’s FOURIER trial, revealed in March 2017, revealed evolocumab significantly reduced the risk of cardiovascular events and were supported by long-term safety data.

0
No votes yet
Name: Top Stories

Copyright © 2018 National Lipid Association. All Rights Reserved.

Privacy Policy Terms of Service